<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Treatment of large granular lymphocyte leukemia
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Treatment of large granular lymphocyte leukemia
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Treatment of large granular lymphocyte leukemia
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Thierry Lamy, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard A Larson, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alan G Rosmarin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jun 03, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Large granular lymphocyte (LGL) leukemia is characterized by peripheral blood and marrow lymphocytic infiltration with clonal LGLs, splenomegaly, and cytopenias, most commonly neutropenia.
        </p>
        <p>
         The LGL is a morphologically distinct lymphoid subset that is larger than most circulating lymphocytes and has characteristic azurophilic granules containing acid hydrolases (
         <a class="graphic graphic_picture graphicRef69027" href="/z/d/graphic/69027.html" rel="external">
          picture 1
         </a>
         ). LGLs comprise 10 to 15 percent of normal peripheral blood mononuclear cells. The absolute number of LGLs in the peripheral blood of normal subjects is 200 to 400/microL.
        </p>
        <p>
         LGLs arise from two major lineages [
         <a href="#rid1">
          1,2
         </a>
         ]. Approximately 85 percent of normal LGLs have a natural killer (NK) cell phenotype and only 15 percent are derived from T cells. The phenotypes of LGLs in LGL leukemia, however, are just the opposite:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          CD3-positive T cell lineage
         </strong>
         – Approximately 85 percent of circulating LGLs are CD3 positive (+), CD8+, CD57+, CD56 negative (-) T cells, representing in vivo antigen-activated effector-memory cytotoxic T cells.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          CD3-negative NK cell lineage
         </strong>
         – The remaining 15 percent of circulating LGLs are CD3-, CD16+, and/or CD56+ NK cells. It had been postulated that such NK cells mediate non-major histocompatibility complex (MHC)-restricted cytotoxicity. It is now established that NK cells possess specific receptors for MHC class I molecules named "killer-cell Ig-like inhibitory receptor" (KIR) and "killer-cell activating receptor" (KAR). Interactions between these receptors and MHC class I molecules on target cells may inhibit or activate NK cell-mediated cytotoxicity.
        </p>
        <p>
        </p>
        <p>
         LGL leukemia can arise from the clonal proliferation of LGLs of T cell or NK cell lineage. The management of LGL leukemia will be discussed here.
        </p>
        <p>
         The etiology, clinical features, and diagnosis of T cell LGL leukemia and the diagnosis and management of NK cell LGL leukemia are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/16360.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of T cell large granular lymphocyte leukemia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7489.html" rel="external">
          "Large granular lymphocyte leukemia in rheumatoid arthritis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4538.html" rel="external">
          "Natural killer (NK) cell large granular lymphocyte leukemia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H807754466">
         <span class="h1">
          PRETREATMENT EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with LGL leukemia should undergo a pretreatment evaluation to determine the extent of disease, patient performance status (
         <a class="graphic graphic_table graphicRef58785 graphicRef72901" href="/z/d/graphic/58785.html" rel="external">
          table 1A-B
         </a>
         ), and assessment of comorbidities that are likely to have an impact on treatment options.
        </p>
        <p>
         In addition to a history and physical examination, it is our practice to perform the following pretreatment studies in patients with LGL leukemia:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Complete blood count with differential.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Unilateral bone marrow aspirate and biopsy is recommended if the diagnosis is uncertain. The specimen should be evaluated microscopically and by immunophenotyping, cytochemistry, and conventional cytogenetics. (See
         <a class="medical medical_review" href="/z/d/html/16360.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of T cell large granular lymphocyte leukemia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with childbearing potential should receive counseling about the potential effect of treatment on their fertility and options for fertility-preserving measures. (See
         <a class="medical medical_review" href="/z/d/html/7440.html" rel="external">
          "Fertility and reproductive hormone preservation: Overview of care prior to gonadotoxic therapy or surgery"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H306820993">
         <span class="h1">
          MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Not all patients with LGL leukemia require treatment at the time of diagnosis.
        </p>
        <p class="headingAnchor" id="H1202974597">
         <span class="h2">
          Asymptomatic patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         For newly diagnosed patients with asymptomatic LGL leukemia, we suggest observation rather than immediate treatment.
        </p>
        <p>
         During the period of observation, we perform a complete blood count (CBC) with differential every 6 to 12 months, along with a clinical examination. Patients are encouraged to contact their health care providers sooner if they have symptoms worrisome of disease progression (eg, recurrent infections, fatigue, dyspnea, bleeding).
        </p>
        <p class="headingAnchor" id="H3125407853">
         <span class="h2">
          Symptomatic patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment is typically reserved for patients with symptomatic disease because LGL leukemia cannot be cured by current treatments and most cases have an indolent clinical behavior (median survival &gt;10 years). Two-thirds of patients ultimately require therapy, most commonly because of recurrent infection secondary to severe neutropenia [
         <a href="#rid3">
          3
         </a>
         ]. Rare spontaneous remissions of LGL leukemia have been documented.
        </p>
        <p>
         The main goal of treatment for patients with LGL leukemia is the relief of symptoms, and especially a reduction in infections associated with neutropenia. Although intuitively sensible, it remains unclear whether achievement of hematologic improvement prolongs survival.
        </p>
        <p>
         Treatment is indicated for relief of symptoms or life-threatening peripheral blood cytopenias:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Severe neutropenia (absolute neutrophil count &lt;500/microL)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Moderate neutropenia (absolute neutrophil count &lt;1000/microL) with recurrent infections
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Symptomatic or transfusion dependent anemia
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Severe thrombocytopenia (&lt;50,000/microL), which is a very rare event
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Associated autoimmune conditions (eg, rheumatoid arthritis) requiring therapy
        </p>
        <p>
        </p>
        <p>
         Some patients with severe neutropenia as their only symptom may be reluctant to start treatment with immunosuppressive agents. Most experts initiate immunosuppressive therapy in such patients. A less attractive alternative is the intermittent use of antibiotics and granulocyte colony-stimulating factor (G-CSF) during febrile episodes. G-CSF can result in a transient partial correction of the neutropenia in such settings [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H30">
         <span class="h1">
          INITIAL TREATMENT
         </span>
        </p>
        <p class="headingAnchor" id="H9327497">
         <span class="h2">
          Choice of therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is no standard treatment regimen for symptomatic LGL leukemia. Although experts prefer different specific regimens, there is general agreement that immunosuppressive therapy (ie,
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         ,
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         ) is the cornerstone of initial treatment [
         <a href="#rid5">
          5-8
         </a>
         ]. The various immunosuppressive treatments have not been directly compared with one another in a prospective fashion, and data come primarily from small, retrospective case series. These series have used different response criteria and provide little information regarding time to response, response and treatment duration, and time to treatment failure.
        </p>
        <p>
         The most promising results have been reported following the use of low-dose oral
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         ,
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         , or
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         , either as single agents or in combination with
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         [
         <a href="#rid2">
          2,9-11
         </a>
         ]. Prednisone may hasten the initial response when administered as adjunctive therapy with another first-line immunosuppressive agent. However, treatment with single-agent prednisone is inadvisable because it has a low response rate and does not reduce LGL clones [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
         A choice among immunosuppressive treatments is primarily made based upon the clinical setting and clinician experience [
         <a href="#rid5">
          5
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neutropenia
         </strong>
         – We prefer oral
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         (10 mg/m
         <sup>
          2
         </sup>
         weekly) with or without
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         for patients with neutropenia as their primary symptom. For patients with an absolute neutrophil count (ANC) &lt;200/microL, oral prednisone (1 mg/kg per day) is administered in addition to the methotrexate for the first month and tapered off by the end of the second month.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Autoimmune disorders
         </strong>
         – We prefer
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         (10 mg/m
         <sup>
          2
         </sup>
         weekly), with or without
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         , for patients with an associated autoimmune disorder (eg, rheumatoid arthritis). In this setting, the use of prednisone is dictated by the accompanying autoimmune disorder. As an example, prednisone may help control joint pain related to rheumatoid arthritis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Anemia
         </strong>
         – We prefer either oral
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         (10 mg/m
         <sup>
          2
         </sup>
         weekly) or oral
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         (100 mg daily) for patients with anemia. While both agents have activity in this setting. Some clinicians favor cyclophosphamide for patients with anemia due to its activity for pure red cell aplasia and for its activity in patients with LGL leukemia who progress after methotrexate; however, treatment with oral cyclophosphamide is limited to no more than 6 to 12 months. Other clinicians favor methotrexate because it can be continued indefinitely.
        </p>
        <p>
        </p>
        <p>
         Response rates with the regimens are described in the following sections. The initial immunosuppressive regimen is continued until disease progression or until the maximum length of treatment is reached. (See
         <a class="local">
          'Response evaluation'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H31">
         <span class="h2">
          Methotrexate
         </span>
         <span class="headingEndMark">
          —
         </span>
         Weekly low-dose oral
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         (10 mg/m
         <sup>
          2
         </sup>
         weekly) with or without
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         is the preferred initial therapy for most patients with LGL leukemia, especially for patients with neutropenia as their primary abnormality and for patients with an associated autoimmune disorder. When compiling all the results reported in the literature, responses are seen in approximately half of patients, with a time to response ranging from 2 to 12 weeks [
         <a href="#rid5">
          5
         </a>
         ]. The median duration of response ranges from two to four years.
        </p>
        <p>
         The following are the largest studies investigating
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         in this population:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An initial prospective study evaluated the efficacy of oral low-dose pulse
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         in 10 patients with T-LGL leukemia [
         <a href="#rid13">
          13
         </a>
         ]. Methotrexate was started at a dose of 5.0 to 7.5 mg orally, given once per week in split AM and PM doses, and gradually increased to 15 to 20 mg/week (10 mg/m
         <sup>
          2
         </sup>
         per week) over one to three months. In patients receiving
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         prior to starting methotrexate (in doses of 20 to 60 mg/day orally), the addition of methotrexate allowed reduction of the daily dose of prednisone to as low as 0 to 10 mg/day, without losing its effectiveness on reversal of neutropenia. The complete remission rate was 50 percent; a molecular remission was observed in three of the five patients achieving complete remission.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A subsequent retrospective case series of patients with LGL leukemia, which included 201 patients with T-LGL leukemia, reported an overall response rate (ORR) of 55 percent (21 percent complete) in 62 patients treated with
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a phase II Eastern Cooperative Oncology Group (ECOG) study of 55 patients with LGL leukemia, initial treatment consisted of weekly oral
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         plus daily oral
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         , which was replaced by daily oral
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         and prednisone for those not responding after four months of treatment [
         <a href="#rid9">
          9
         </a>
         ]. The ORR after methotrexate was 38 percent. Those not responding to methotrexate had an ORR of 64 percent to cyclophosphamide. Serum biomarkers confirmed the inflammatory milieu of LGL leukemia but were not predictive of response. A gene expression profile correlated with response to methotrexate and appeared to be STAT3 mutation driven.
        </p>
        <p>
        </p>
        <p>
         Low-dose oral
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         is generally well tolerated and can be continued long term. Common toxicities associated with methotrexate include (see
         <a class="medical medical_review" href="/z/d/html/7509.html" rel="external">
          "Major side effects of low-dose methotrexate"
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Gastrointestinal problems such as nausea, stomach upset, and loose stools
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stomatitis or soreness of the mouth
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Macular punctate rash that usually occurs on the extremities and spares the trunk
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Central nervous system problems including headache, fatigue, or impaired ability to concentrate
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Alopecia
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fever, but infection should be excluded
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hematologic abnormalities, particularly macrocytosis
        </p>
        <p>
        </p>
        <p>
         One or more of these side effects are seen in some form, at some time, in most patients. Less common, but potentially serious, side effects include hepatotoxicity, pulmonary toxicity, myelosuppression, and nephrotoxicity. Prior to initiating
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         therapy, patients should be screened for hepatitis B and hepatitis C virus infections and should undergo a baseline chest radiograph. Hepatic function and complete blood counts should be monitored every four to eight weeks while on therapy. We do not routinely administer
         <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">
          folic acid
         </a>
         to most patients receiving weekly methotrexate; however, we supplement folic acid at a dose of 1 mg/day for patients who develop mouth sores or other toxicities. (See
         <a class="medical medical_review" href="/z/d/html/7509.html" rel="external">
          "Major side effects of low-dose methotrexate"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H35829049">
         <span class="h2">
          Cyclophosphamide
         </span>
         <span class="headingEndMark">
          —
         </span>
         Low-dose oral
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         (50 to 100 mg daily) has demonstrated an ORR of 55 to 65 percent in patients with previously untreated LGL leukemia [
         <a href="#rid3">
          3,11,14-16
         </a>
         ]. This agent, along with
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         , may be particularly effective in patients with LGL leukemia and pure red cell aplasia [
         <a href="#rid3">
          3,14,17,18
         </a>
         ]. Preliminary data from United States, Italian, and French registries suggest that oral cyclophosphamide used as first-line therapy may be a good option either in neutropenic or anemic patients [
         <a href="#rid19">
          19
         </a>
         ]. In addition, responses have been reported in a majority of patients who have failed treatment with
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         [
         <a href="#rid12">
          12
         </a>
         ]. The time to response ranges from one to four months. The median duration of response is unknown. Cyclophosphamide should not be administered for longer than 6 to 12 months for responders because the risk of toxicity is related to the cumulative dose of medication.
        </p>
        <p>
         Major toxicities associated with long-term
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         therapy include bone marrow suppression with accompanying cytopenias, increased risk of infection, infertility, and an increased risk of developing secondary malignancies. Cyclophosphamide is teratogenic and contraindicated in pregnant females. Both cystitis and bladder cancer are associated with cyclophosphamide therapy. To minimize bladder toxicity, patients should be advised to take cyclophosphamide in the morning and to drink at least eight glasses (240 mL each) of water daily. (See
         <a class="medical medical_review" href="/z/d/html/7987.html" rel="external">
          "General toxicity of cyclophosphamide in rheumatic diseases"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H32">
         <span class="h2">
          Cyclosporine
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          Cyclosporine
         </a>
         A, administered at varying doses, has demonstrated an ORR of 56 percent with response rates ranging in different case series from 21 to 100 percent [
         <a href="#rid5">
          5
         </a>
         ]. Responses are seen despite survival of the leukemic LGL clone, and relapses on therapy are not uncommon [
         <a href="#rid20">
          20,21
         </a>
         ]. Responses have been reported in patients with pure red cell aplasia and in patients with resistant disease. One series reported higher response rates among patients with an HLADR4 phenotype (present in 32 percent of LGL leukemia and 90 percent of LGL leukemia associated with rheumatoid arthritis) [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
         The following case series reported on
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         for the treatment of LGL leukemia [
         <a href="#rid11">
          11,12,15-17,21-26
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A case series of 229 patients with LGL leukemia (201 patients with T-LGL) reported an ORR of 21 percent (4 percent complete) in 24 patients treated with
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In another study,
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         (5 to 10 mg/kg per day orally in two divided doses for at least three months, adjusted to a therapeutic blood level of 200 to 400 ng/mL) was given to 25 subjects with anemia and/or neutropenia associated with T-LGL leukemia [
         <a href="#rid22">
          22
         </a>
         ]. Fourteen patients responded with sustained improvement in neutrophil counts or transfusion independence, seven of whom had complete normalization of blood counts. On multivariate analysis the presence of HLA-DR4 was highly predictive of response to cyclosporine.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          Cyclosporine
         </a>
         (initial dose 1.0 to 1.5 mg/kg orally every 12 hours), with or without low-dose granulocyte-macrophage colony-stimulating factor (GM-CSF), has led to a return of normal neutrophil counts in five severely neutropenic subjects with initial absolute neutrophil counts &lt;500/microL [
         <a href="#rid20">
          20,21
         </a>
         ]. Abnormal LGL populations persisted in these patients and neutropenia returned when cyclosporine was discontinued. Two of these patients were able to maintain normal neutrophil levels for eight years with continuous cyclosporine therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In one study, clonal cytogenetic abnormalities were associated with a poor response to immunosuppressive therapy [
         <a href="#rid17">
          17
         </a>
         ]. However, five patients were successfully treated, with starting doses of 12 mg/kg per day in divided doses for four patients, and 150 mg twice daily for the remaining patient.
        </p>
        <p>
        </p>
        <p>
         Low-dose oral
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         can be continued long-term, but its use is limited by drug interactions and side effects. Cyclosporine is metabolized by the hepatic cytochrome P450 3A enzymes and has a variety of important drug interactions. Toxicities with long-term use include gastrointestinal distress, nephrotoxicity, hypertension, neurotoxicity, and secondary malignancies. Blood pressure, creatinine, blood urea nitrogen, blood glucose, liver function tests, potassium, and magnesium should be monitored every two weeks for the first three months of therapy and every one to two months thereafter. Plasma creatinine is adequate for follow-up of the renal function; an increase above baseline by more than 30 percent (even if it is still in the normal range) requires a decrease of the dose or a temporary discontinuation of the drug. Similarly, hypertension during therapy should prompt reduction in dose or initiation of antihypertensive therapy. (See
         <a class="medical medical_review" href="/z/d/html/7995.html" rel="external">
          "Pharmacology of cyclosporine and tacrolimus"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1147328393">
         <span class="h1">
          RESPONSE EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Four months following the initiation of therapy, the response to treatment should be evaluated by history, physical examination, and complete blood count with differential [
         <a href="#rid5">
          5
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Complete response
         </strong>
         – A hematologic complete response is defined as the complete normalization of blood counts (ie, hemoglobin &gt;12 g/dL; platelets ≥150,000/microL; absolute neutrophil count &gt;1500/microL; absolute lymphocyte count &lt;4000/microL) in the setting of a circulating LGL count of less than 500/microL.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Partial response
         </strong>
         – A hematologic partial response is defined as an improvement in blood counts that does not meet criteria for complete remission (eg, an absolute neutrophil count &gt;500/microL or decreasing transfusion requirements).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment failure
         </strong>
         – Treatment failure is defined as an inability to achieve an at least partial response after four months of therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Progressive disease
         </strong>
         – Progressive disease is defined as a worsening of cytopenias, hepatomegaly, or splenomegaly.
        </p>
        <p>
        </p>
        <p>
         Patients who achieve an at least partial response should continue treatment until treatment failure or until the maximum number of months has elapsed for that regimen, whichever is shorter.
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          Methotrexate
         </a>
         and
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         can be continued indefinitely, as tolerated. In contrast,
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         should not be administered for longer than 6 to 12 months for responders. Patients who fail to attain an at least partial response should be considered for a new therapy.
        </p>
        <p>
         A decision to continue treatment in a patient with a complete remission must balance the toxicity of treatment with the risk of recurrence. There are no formal studies that have addressed this question. Some clinicians choose to discontinue
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         in patients who have maintained a complete remission (especially a molecular remission) for one or two years. In our experience, cessation of methotrexate usually leads to eventual slow recurrence of the clinical manifestations of LGL leukemia. Retreatment with methotrexate at that time is usually successful again. In contrast, cessation of
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         is associated with rapid recurrence of cytopenias. Therefore, a drug holiday from cyclosporine is not recommended.
        </p>
        <p class="headingAnchor" id="H1147331490">
         <span class="h1">
          TREATMENT OF RELAPSED OR RESISTANT DISEASE
         </span>
         <span class="headingEndMark">
          —
         </span>
         The treatment of patients with relapsed, resistant, or refractory disease depends upon the initial treatment regimen and the timing of progression. For our purposes [
         <a href="#rid5">
          5
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Relapsed disease
         </strong>
         refers to the progression of disease after an initial response.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Resistant disease
         </strong>
         refers to the inability to achieve an at least partial response after four months of therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Refractory disease
         </strong>
         refers to the failure of the three major immunosuppressive drugs (ie,
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         ,
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         , and
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H35829953">
         <span class="h2">
          Relapsed disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         The treatment of patients with LGL leukemia that relapses after an initial response depends upon the timing of relapse. Patients not receiving active treatment at the time of relapse may respond to a second trial of the initial treatment regimen. More commonly, such patients and those who relapse on active therapy may respond to a trial of another one of the three major immunosuppressive drugs (ie,
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         ,
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         , and
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         ). (See
         <a class="local">
          'Initial treatment'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H35829961">
         <span class="h2">
          Resistant disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with LGL leukemia that is refractory to initial treatment should undergo a trial of another one of the three major immunosuppressive drugs (ie,
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         ,
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         , and
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         ). As described above, responses to cyclophosphamide have been reported in a majority of patients who have failed treatment with methotrexate [
         <a href="#rid12">
          12
         </a>
         ]. Some experts prefer cyclosporine for the treatment of patients with resistant disease manifesting as anemia. (See
         <a class="local">
          'Initial treatment'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H35830014">
         <span class="h2">
          Refractory or aggressive disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Refractory disease refers to those patients who have persistent LGL leukemia despite trials of the three major immunosuppressive drugs (ie,
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         ,
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         , and
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         ). The optimal treatment of such patients is unknown and often the best option is to enroll on a clinical trial. Purine analogs and
         <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">
          alemtuzumab
         </a>
         have demonstrated activity in LGL leukemia and may be considered. Splenectomy may correct neutropenia, hemolytic anemia, or provide symptomatic relief from splenomegaly, but may induce high-risk secondary infections.
        </p>
        <p>
         Aggressive forms of LGL leukemia have been described with a clinical behavior close to aggressive lymphoma. There is no consensus regarding the preferred treatment approach for such patients, and clinical practice varies. Some clinicians have proposed the use autologous or allogeneic hematopoietic cell transplantation (HCT). A retrospective study by the European Group for Blood and Marrow Transplantation (EGBMT) reported overall survival and progression-free survival at two years of 60 and 43 percent, respectively, for the entire cohort of 15 patients who underwent either autologous or allogeneic HCT (5 and 10 patients, respectively) [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1147331534">
         <span class="h3">
          Alemtuzumab
         </span>
         <span class="headingEndMark">
          —
         </span>
         The monoclonal antibody
         <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">
          alemtuzumab
         </a>
         targets CD52 expressed on the surface of T cell LGL leukemia [
         <a href="#rid28">
          28
         </a>
         ]. Case reports and small case series have demonstrated responses in half of patients with refractory disease [
         <a href="#rid12">
          12,23,25,29-35
         </a>
         ]. As an example, a phase II trial of 25 patients demonstrated an overall response of 56 percent [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
         Patients treated with
         <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">
          alemtuzumab
         </a>
         are immunocompromised and are therefore at risk for potentially lethal opportunistic infections with organisms such as
         <em>
          Pneumocystis jirovecii
         </em>
         (previously
         <em>
          P. carinii
         </em>
         ) and cytomegalovirus. All patients planning to receive alemtuzumab should undergo serology testing for cytomegalovirus (IgM and IgG), herpes simplex virus (IgM and IgG), hepatitis B (HBsAg and anti-HBc), and hepatitis C (anti-HCV). While prophylaxis for such infections is generally given, clinicians need to consider these organisms when patients become unwell. (See
         <a class="medical medical_review" href="/z/d/html/1406.html" rel="external">
          "Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in patients without HIV"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8291.html" rel="external">
          "Overview of diagnostic tests for cytomegalovirus infection"
         </a>
         .)
        </p>
        <p>
         Autoimmune encephalitis (AIE) has been reported in association with
         <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">
          alemtuzumab
         </a>
         treatment [
         <a href="#rid37">
          37
         </a>
         ]. Patients with symptoms such as subacute onset of memory impairment, altered mental status, psychiatric symptoms, neurological findings, and/or seizures should be evaluated for AIE. (See
         <a class="medical medical_review" href="/z/d/html/15759.html" rel="external">
          "Autoimmune (including paraneoplastic) encephalitis: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H35830215">
         <span class="h3">
          Purine analogs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Data regarding the efficacy of purine analogs (eg, 2-chlorodeoxyadenosine,
         <a class="drug drug_general" data-topicid="9756" href="/z/d/drug information/9756.html" rel="external">
          pentostatin
         </a>
         , and
         <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">
          fludarabine
         </a>
         ) for the treatment of LGL leukemia are limited to less than 100 published cases [
         <a href="#rid11">
          11,12,23,25,38-44
         </a>
         ]. The overall response rate in reported cases is approximately 80 percent with most remissions occurring after the first course of therapy [
         <a href="#rid5">
          5
         </a>
         ]. Remissions lasting up to six years have been reported.
        </p>
        <p>
         Patients receiving therapy with purine analogs are at increased risk for several opportunistic infections. The use of antimicrobials in these patients is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/1405.html" rel="external">
          "Prevention of infections in patients with chronic lymphocytic leukemia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/95716.html" rel="external">
          "Risk of infections in patients with chronic lymphocytic leukemia", section on 'Purine analogs'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3277741081">
         <span class="h3">
          Ruxolitinib
         </span>
         <span class="headingEndMark">
          —
         </span>
         The JAK2 inhibitor,
         <a class="drug drug_general" data-topicid="17096" href="/z/d/drug information/17096.html" rel="external">
          ruxolitinib
         </a>
         , was reported to achieve durable remissions in patients with refractory LGL leukemia.
        </p>
        <p>
         JAK-STAT signaling has been proposed as a potential therapeutic target in LGL leukemia [
         <a href="#rid45">
          45,46
         </a>
         ]. Treatment with
         <a class="drug drug_general" data-topicid="17096" href="/z/d/drug information/17096.html" rel="external">
          ruxolitinib
         </a>
         achieved a durable complete remission in one patient and a very good partial response (&gt;1 year) in another patient with refractory LGL leukemia; neither patient experienced adverse effects of ruxolitinib [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
         Prior to initiating
         <a class="drug drug_general" data-topicid="17096" href="/z/d/drug information/17096.html" rel="external">
          ruxolitinib
         </a>
         , patients should be counseled about the risk of ruxolitinib withdrawal syndrome and screened for tuberculosis, as described separately.
        </p>
        <p class="headingAnchor" id="H35830444">
         <span class="h3">
          Splenectomy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Case reports and small case series of patients with LGL leukemia have noted responses in up to 56 percent, with the most recent case series demonstrating low response rates [
         <a href="#rid3">
          3,5,12,15,48-52
         </a>
         ]. Splenectomy may be considered only for patients with resistant disease who have symptomatic splenomegaly or evidence of autoimmune cytopenias.
        </p>
        <p class="headingAnchor" id="H35829696">
         <span class="h3">
          Other therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is a paucity of data regarding the use of other treatment regimens for LGL leukemia. While occasional responses have been noted in case reports, more aggressive treatment, such as the use of allogeneic HCT or chemotherapy regimens used for more aggressive lymphomas (eg, CHOP or hyper-CVAD), has had disappointing results [
         <a href="#rid1">
          1,53,54
         </a>
         ]. Response rates with these regimens are poor and most patients die within one year after the start of treatment. One possible reason for the adverse outcome is that LGL leukemic cells, like their normal counterparts (NK or T cell cytotoxic cells), constitutively express high levels of P glycoprotein (PgP), the product of the multidrug resistance gene (MDR1) [
         <a href="#rid55">
          55-58
         </a>
         ].
        </p>
        <p>
         A report from France described two cases of T cell LGL leukemia in patients with rheumatoid arthritis (RA) that responded to treatment with the B cell monoclonal antibody
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         [
         <a href="#rid59">
          59
         </a>
         ]. Rituximab appears somewhat counterintuitive for the treatment of a T cell malignancy; however, there are profound abnormalities in B cell function as evidenced by autoantibodies, circulating immune complexes, and hypergammaglobulinemia in LGL leukemia. Other cases showing efficacy of rituximab in the context of RA and LGL leukemia have been reported [
         <a href="#rid60">
          60,61
         </a>
         ]. Further study is needed to determine whether there is a role for rituximab in this setting, especially in absence of associated RA.
        </p>
        <p class="headingAnchor" id="H1147330155">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         LGL leukemia is usually a chronic disease, and some patients may be asymptomatic for long periods of time [
         <a href="#rid62">
          62
         </a>
         ]. The first large series published in the literature included 151 patients; survival was approximately 85 percent at a mean follow-up of two to four years [
         <a href="#rid62">
          62
         </a>
         ]. Another study of 68 patients reported a median survival greater than 10 years [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         In multivariate analyses, risk factors associated with poor clinical outcome were fever at diagnosis, low percentage of CD57+ cells, and low (&lt;5000/microL) or high (&gt;20,000/microL) peripheral LGL counts [
         <a href="#rid62">
          62
         </a>
         ]. In another study, severe neutropenia or "B" symptoms (ie, fever, weight loss, night sweats) were associated with a lower probability of complete remission.
        </p>
        <p class="headingAnchor" id="H1147329114">
         <span class="h1">
          CLINICAL TRIALS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Often there is no better therapy to offer a patient than enrollment onto a well-designed, scientifically valid, peer-reviewed clinical trial. Additional information and instructions for referring a patient to an appropriate research center can be obtained from the United States National Institutes of Health (
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.clinicaltrials.gov%2F&amp;token=NK91I08KOJ1eJ1hT1o%2FoHgJu4vbbEBRl2V0d48fIIMDpbZTpeZvuNaOE2M5VxYDS&amp;TOPIC_ID=4536" target="_blank">
          www.clinicaltrials.gov
         </a>
         ).
        </p>
        <p>
         Ongoing studies are comparing available drugs (eg,
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         versus
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         ) and new drugs. Agents under investigation include some approved for other diseases (eg, Janus kinase inhibitor,
         <a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">
          tofacitinib
         </a>
         ), other novel drugs (eg, STAT3 inhibitors), and novel antibodies.
        </p>
        <p>
         Considering the role of IL-15 in the pathogenesis of LGL leukemia, monoclonal antibodies targeting IL-15 were evaluated, but a phase I trial using a humanized MiK-beta-1 monoclonal antibody against the shared IL-2/IL-15R subunit (CD122) showed disappointing results [
         <a href="#rid63">
          63,64
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2670437246">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/133137.html" rel="external">
          "Society guideline links: Large granular lymphocyte leukemia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H39">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Large granular lymphocyte (LGL) leukemia
         </strong>
         – LGL leukemia is characterized by peripheral blood and marrow lymphocytic infiltration with clonal LGLs, splenomegaly, and cytopenias, most commonly neutropenia. LGL leukemia can arise from the clonal proliferation of LGLs of T cell or natural killer (NK) cell lineage.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         – Not all patients with LGL leukemia require treatment at the time of diagnosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Asymptomatic
         </strong>
         – For patients with asymptomatic T-LGL, we suggest close observation rather than immediate treatment (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Asymptomatic patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Symptomatic
         </strong>
         – We reserve treatment for patients with symptoms related to neutropenia, anemia, thrombocytopenia, or associated autoimmune conditions requiring therapy. (See
         <a class="local">
          'Symptomatic patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
         – There is no standard treatment regimen for symptomatic LGL leukemia, but there is general agreement that immunosuppressive therapy (ie,
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         ,
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         ) is the cornerstone of initial treatment. A choice among immunosuppressive treatments is primarily made based upon the clinical setting and physician experience:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Neutropenia
         </strong>
         – For patients with LGL leukemia and neutropenia as their primary symptom, we suggest
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         with or without
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         rather than other immunosuppressive therapies (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). We administer oral methotrexate 10 mg/m
         <sup>
          2
         </sup>
         weekly. For patients with an absolute neutrophil count &lt;200/microL, oral prednisone (1 mg/kg per day) is administered in addition to the methotrexate for the first month and tapered off by the end of the second month. (See
         <a class="local">
          'Methotrexate'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Autoimmune disorders
         </strong>
         – For patients with LGL leukemia and an associated autoimmune disorder, we suggest treatment with
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         , with or without
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). In this setting, the use of prednisone is dictated by the accompanying autoimmune disorder. (See
         <a class="local">
          'Methotrexate'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Anemia
         </strong>
         – For patients with LGL leukemia and anemia as their primary symptom, we suggest either oral
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         or oral
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         , rather than
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). While both of these agents have demonstrated activity in this setting, some clinicians prefer cyclophosphamide for patients with anemia at least partially due to its demonstrated activity in patients with pure red cell aplasia. Other clinicians prefer methotrexate because it can be continued indefinitely as long as it is tolerated, whereas treatment with oral cyclophosphamide is limited to no more than 6 to 12 months. (See
         <a class="local">
          'Cyclophosphamide'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Response evaluation
         </strong>
         – Four months following the initiation of therapy, the response to treatment should be evaluated by history, physical examination, and complete blood count with differential. Patients with at least a partial response should continue treatment until treatment failure or until the maximum number of months has elapsed for that regimen, whichever is shorter.
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          Methotrexate
         </a>
         and
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         can be continued indefinitely, as tolerated. In contrast,
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         should not be administered for longer than 6 to 12 months for responders. (See
         <a class="local">
          'Response evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Relapsed, refractory, or resistant disease
         </strong>
         – Treatment of patients with relapsed, resistant, or refractory disease depends upon the initial treatment regimen and the timing of progression. (See
         <a class="local">
          'Treatment of relapsed or resistant disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4167723932">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Thomas P Loughran, Jr, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Loughran TP Jr. Clonal diseases of large granular lymphocytes. Blood 1993; 82:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lamy T, Loughran TP Jr. Clinical features of large granular lymphocyte leukemia. Semin Hematol 2003; 40:185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dhodapkar MV, Li CY, Lust JA, et al. Clinical spectrum of clonal proliferations of T-large granular lymphocytes: a T-cell clonopathy of undetermined significance? Blood 1994; 84:1620.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lamy T, LePrise PY, Amiot L, et al. Response to granulocyte-macrophage colony-stimulating factor (GM-CSF) but not to G-CSF in a case of agranulocytosis associated with large granular lymphocyte (LGL) leukemia. Blood 1995; 85:3352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lamy T, Loughran TP Jr. How I treat LGL leukemia. Blood 2011; 117:2764.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dearden CE, Johnson R, Pettengell R, et al. Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma). Br J Haematol 2011; 153:451.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dearden C. Large granular lymphocytic leukaemia pathogenesis and management. Br J Haematol 2011; 152:273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lamy T, Moignet A, Loughran TP Jr. LGL leukemia: from pathogenesis to treatment. Blood 2017; 129:1082.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loughran TP Jr, Zickl L, Olson TL, et al. Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998). Leukemia 2015; 29:886.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ravandi F, O'Brien S. Chronic lymphoid leukemias other than chronic lymphocytic leukemia: diagnosis and treatment. Mayo Clin Proc 2005; 80:1660.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Osuji N, Matutes E, Tjonnfjord G, et al. T-cell large granular lymphocyte leukemia: A report on the treatment of 29 patients and a review of the literature. Cancer 2006; 107:570.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bareau B, Rey J, Hamidou M, et al. Analysis of a French cohort of patients with large granular lymphocyte leukemia: a report on 229 cases. Haematologica 2010; 95:1534.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loughran TP Jr, Kidd PG, Starkebaum G. Treatment of large granular lymphocyte leukemia with oral low-dose methotrexate. Blood 1994; 84:2164.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Go RS, Li CY, Tefferi A, Phyliky RL. Acquired pure red cell aplasia associated with lymphoproliferative disease of granular T lymphocytes. Blood 2001; 98:483.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mohan SR, Maciejewski JP. Diagnosis and therapy of neutropenia in large granular lymphocyte leukemia. Curr Opin Hematol 2009; 16:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fujishima N, Sawada K, Hirokawa M, et al. Long-term responses and outcomes following immunosuppressive therapy in large granular lymphocyte leukemia-associated pure red cell aplasia: a Nationwide Cohort Study in Japan for the PRCA Collaborative Study Group. Haematologica 2008; 93:1555.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lacy MQ, Kurtin PJ, Tefferi A. Pure red cell aplasia: association with large granular lymphocyte leukemia and the prognostic value of cytogenetic abnormalities. Blood 1996; 87:3000.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Go RS, Lust JA, Phyliky RL. Aplastic anemia and pure red cell aplasia associated with large granular lymphocyte leukemia. Semin Hematol 2003; 40:196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moignet A, Hasanali Z, Zambello R, et al. Cyclophosphamide as a first-line therapy in LGL leukemia. Leukemia 2014; 28:1134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gabor EP, Mishalani S, Lee S. Rapid response to cyclosporine therapy and sustained remission in large granular lymphocyte leukemia. Blood 1996; 87:1199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sood R, Stewart CC, Aplan PD, et al. Neutropenia associated with T-cell large granular lymphocyte leukemia: long-term response to cyclosporine therapy despite persistence of abnormal cells. Blood 1998; 91:3372.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Battiwalla M, Melenhorst J, Saunthararajah Y, et al. HLA-DR4 predicts haematological response to cyclosporine in T-large granular lymphocyte lymphoproliferative disorders. Br J Haematol 2003; 123:449.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aribi A, Huh Y, Keating M, et al. T-cell large granular lymphocytic (T-LGL) leukemia: experience in a single institution over 8 years. Leuk Res 2007; 31:939.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pawarode A, Wallace PK, Ford LA, et al. Long-term safety and efficacy of cyclosporin A therapy for T-cell large granular lymphocyte leukemia. Leuk Lymphoma 2010; 51:338.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fortune AF, Kelly K, Sargent J, et al. Large granular lymphocyte leukemia: natural history and response to treatment. Leuk Lymphoma 2010; 51:839.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bible KC, Tefferi A. Cyclosporine A alleviates severe anaemia associated with refractory large granular lymphocytic leukaemia and chronic natural killer cell lymphocytosis. Br J Haematol 1996; 93:406.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marchand T. Hematopoietic stem cell transplantation for T-cell large granular lymphocyte leukemia: a retrospective study of the European Society for Blood and Marrow Transplantation. Leukemia 2015; 29:2427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Osuji N, Del Giudice I, Matutes E, et al. CD52 expression in T-cell large granular lymphocyte leukemia--implications for treatment with alemtuzumab. Leuk Lymphoma 2005; 46:723.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mohan SR, Clemente MJ, Afable M, et al. Therapeutic implications of variable expression of CD52 on clonal cytotoxic T cells in CD8+ large granular lymphocyte leukemia. Haematologica 2009; 94:1407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ru X, Liebman HA. Successful treatment of refractory pure red cell aplasia associated with lymphoproliferative disorders with the anti-CD52 monoclonal antibody alemtuzumab (Campath-1H). Br J Haematol 2003; 123:278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenblum MD, LaBelle JL, Chang CC, et al. Efficacy of alemtuzumab treatment for refractory T-cell large granular lymphocytic leukemia. Blood 2004; 103:1969.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schützinger C, Gaiger A, Thalhammer R, et al. Remission of pure red cell aplasia in T-cell receptor gammadelta-large granular lymphocyte leukemia after therapy with low-dose alemtuzumab. Leukemia 2005; 19:2005.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Au WY, Lam CC, Chim CS, et al. Alemtuzumab induced complete remission of therapy-resistant pure red cell aplasia. Leuk Res 2005; 29:1213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ravandi F, Aribi A, O'Brien S, et al. Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. J Clin Oncol 2009; 27:5425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Monjanel H, Hourioux C, Arbion F, et al. Rapid and durable molecular response of refractory T-cell large granular lymphocyte leukemia after alemtuzumab treatment. Leuk Res 2010; 34:e197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dumitriu B, Ito S, Feng X, et al. Alemtuzumab in T-cell large granular lymphocytic leukaemia: interim results from a single-arm, open-label, phase 2 study. Lancet Haematol 2016; 3:e22.
          </a>
         </li>
         <li class="breakAll">
          Highlights of prescribing information: Lemtrada (alemtuzumab). US Food and Drug Administration. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/103948s5185lbl.pdf (Accessed on June 03, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sternberg A, Eagleton H, Pillai N, et al. Neutropenia and anaemia associated with T-cell large granular lymphocyte leukaemia responds to fludarabine with minimal toxicity. Br J Haematol 2003; 120:699.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Edelman MJ, O'Donnell RT, Meadows I. Treatment of refractory large granular lymphocytic leukemia with 2-chlorodeoxyadenosine. Am J Hematol 1997; 54:329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ma SY, Au WY, Chim CS, et al. Fludarabine, mitoxantrone and dexamethasone in the treatment of indolent B- and T-cell lymphoid malignancies in Chinese patients. Br J Haematol 2004; 124:754.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsirigotis P, Venetis E, Kapsimali V, et al. 2-deoxycoformycin in the treatment of T-large granular lymphocyte leukemia. Leuk Res 2003; 27:865.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tse E, Chan JC, Pang A, et al. Fludarabine, mitoxantrone and dexamethasone as first-line treatment for T-cell large granular lymphocyte leukemia. Leukemia 2007; 21:2225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dincol G, Diz-Kuçukkaya R, Bicakci E. T-cell large granular lymphocytic leukaemia: successful response to 2-deoxycoformycin. Neth J Med 2008; 66:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sretenovic A, Antic D, Jankovic S, et al. T-cell large granular lymphocytic (T-LGL) leukemia: a single institution experience. Med Oncol 2010; 27:286.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuusanmäki H, Dufva O, Parri E, et al. Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling. Oncotarget 2017; 8:97516.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dufva O, Kankainen M, Kelkka T, et al. Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target. Nat Commun 2018; 9:1567.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moignet A, Pastoret C, Cartron G, et al. Ruxolitinib for refractory large granular lymphocyte leukemia. Am J Hematol 2021; 96:E368.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Subbiah V, Viny AD, Rosenblatt S, et al. Outcomes of splenectomy in T-cell large granular lymphocyte leukemia with splenomegaly and cytopenia. Exp Hematol 2008; 36:1078.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gentile TC, Hadlock KG, Uner AH, et al. Large granular lymphocyte leukaemia occurring after renal transplantation. Br J Haematol 1998; 101:507.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loughran TP Jr, Starkebaum G, Clark E, et al. Evaluation of splenectomy in large granular lymphocyte leukaemia. Br J Haematol 1987; 67:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Furukawa Y, Tanaka K, Hasuike T, et al. [Chronic lymphocytic leukemia with peripheral T lymphocytes expressing CD 2+, CD 3+, CD 4-, CD 8-, CD 16+, and CD 56+ and lymph-node lymphocytes expressing CD 2+, CD 3-, CD 4-, CD 8-, CD 16+, CD 38+, and CD 56+]. Rinsho Byori 1991; 39:557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brinkman K, van Dongen JJ, van Lom K, et al. Induction of clinical remission in T-large granular lymphocyte leukemia with cyclosporin A, monitored by use of immunophenotyping with Vbeta antibodies. Leukemia 1998; 12:150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alekshun TJ, Tao J, Sokol L. Aggressive T-cell large granular lymphocyte leukemia: a case report and review of the literature. Am J Hematol 2007; 82:481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seebach J, Speich R, Gmür J. Allogeneic bone marrow transplantation for CD3+/TCR gamma delta+ large granular lymphocyte proliferation. Blood 1995; 85:853.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lamy T, Drenou B, Fardel O, et al. Multidrug resistance analysis in lymphoproliferative disease of large granular lymphocytes. Br J Haematol 1998; 100:509.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gupta S, Kim CH, Tsuruo T, Gollapudi S. Preferential expression and activity of multidrug resistance gene 1 product (P-glycoprotein), a functionally active efflux pump, in human CD8+ T cells: a role in cytotoxic effector function. J Clin Immunol 1992; 12:451.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chaudhary PM, Mechetner EB, Roninson IB. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 1992; 80:2735.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamamoto T, Iwasaki T, Watanabe N, et al. Expression of multidrug resistance P-glycoprotein on peripheral blood mononuclear cells of patients with granular lymphocyte-proliferative disorders. Blood 1993; 81:1342.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cornec D, Devauchelle-Pensec V, Jousse-Joulin S, et al. Long-term remission of T-cell large granular lymphocyte leukemia associated with rheumatoid arthritis after rituximab therapy. Blood 2013; 122:1583.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ibrahim U, Parylo S, Kedia S, et al. Large Granular Lymphocytic Leukemia: A Report of Response to Rituximab. Case Rep Hematol 2017; 2017:7506542.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raposo A, Cerqueira M, Costa J, et al. Rheumatoid arthritis and associated large granular lymphocytic leukemia--successful treatment with rituximab. Acta Reumatol Port 2015; 40:384.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pandolfi F, Loughran TP Jr, Starkebaum G, et al. Clinical course and prognosis of the lymphoproliferative disease of granular lymphocytes. A multicenter study. Cancer 1990; 65:341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Waldmann TA, Conlon KC, Stewart DM, et al. Phase 1 trial of IL-15 trans presentation blockade using humanized Mikβ1 mAb in patients with T-cell large granular lymphocytic leukemia. Blood 2013; 121:476.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bilori B, Thota S, Clemente MJ, et al. Tofacitinib as a novel salvage therapy for refractory T-cell large granular lymphocytic leukemia. Leukemia 2015; 29:2427.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 4536 Version 29.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8324214" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Clonal diseases of large granular lymphocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12876667" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Clinical features of large granular lymphocyte leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8068951" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Clinical spectrum of clonal proliferations of T-large granular lymphocytes: a T-cell clonopathy of undetermined significance?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7538825" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Response to granulocyte-macrophage colony-stimulating factor (GM-CSF) but not to G-CSF in a case of agranulocytosis associated with large granular lymphocyte (LGL) leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21190991" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : How I treat LGL leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21480860" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21158751" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Large granular lymphocytic leukaemia pathogenesis and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28115367" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : LGL leukemia: from pathogenesis to treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25306898" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16342661" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Chronic lymphoid leukemias other than chronic lymphocytic leukemia: diagnosis and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16795070" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : T-cell large granular lymphocyte leukemia: A report on the treatment of 29 patients and a review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20378561" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Analysis of a French cohort of patients with large granular lymphocyte leukemia: a report on 229 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7919331" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Treatment of large granular lymphocyte leukemia with oral low-dose methotrexate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11435321" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Acquired pure red cell aplasia associated with lymphoproliferative disease of granular T lymphocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19057202" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Diagnosis and therapy of neutropenia in large granular lymphocyte leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18641028" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Long-term responses and outcomes following immunosuppressive therapy in large granular lymphocyte leukemia-associated pure red cell aplasia: a Nationwide Cohort Study in Japan for the PRCA Collaborative Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8639922" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Pure red cell aplasia: association with large granular lymphocyte leukemia and the prognostic value of cytogenetic abnormalities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12876668" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Aplastic anemia and pure red cell aplasia associated with large granular lymphocyte leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24280867" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Cyclophosphamide as a first-line therapy in LGL leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8562948" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Rapid response to cyclosporine therapy and sustained remission in large granular lymphocyte leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9558395" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Neutropenia associated with T-cell large granular lymphocyte leukemia: long-term response to cyclosporine therapy despite persistence of abnormal cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14617004" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : HLA-DR4 predicts haematological response to cyclosporine in T-large granular lymphocyte lymphoproliferative disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17045649" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : T-cell large granular lymphocytic (T-LGL) leukemia: experience in a single institution over 8 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20038217" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Long-term safety and efficacy of cyclosporin A therapy for T-cell large granular lymphocyte leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20367569" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Large granular lymphocyte leukemia: natural history and response to treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8639439" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Cyclosporine A alleviates severe anaemia associated with refractory large granular lymphocytic leukaemia and chronic natural killer cell lymphocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Hematopoietic stem cell transplantation for T-cell large granular lymphocyte leukemia: a retrospective study of the European Society for Blood and Marrow Transplantation
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16019510" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : CD52 expression in T-cell large granular lymphocyte leukemia--implications for treatment with alemtuzumab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19794084" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Therapeutic implications of variable expression of CD52 on clonal cytotoxic T cells in CD8+ large granular lymphocyte leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14531909" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Successful treatment of refractory pure red cell aplasia associated with lymphoproliferative disorders with the anti-CD52 monoclonal antibody alemtuzumab (Campath-1H).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14976065" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Efficacy of alemtuzumab treatment for refractory T-cell large granular lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16193089" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Remission of pure red cell aplasia in T-cell receptor gammadelta-large granular lymphocyte leukemia after therapy with low-dose alemtuzumab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16111536" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Alemtuzumab induced complete remission of therapy-resistant pure red cell aplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19805674" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20211489" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Rapid and durable molecular response of refractory T-cell large granular lymphocyte leukemia after alemtuzumab treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26765645" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Alemtuzumab in T-cell large granular lymphocytic leukaemia: interim results from a single-arm, open-label, phase 2 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26765645" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Alemtuzumab in T-cell large granular lymphocytic leukaemia: interim results from a single-arm, open-label, phase 2 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12588360" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Neutropenia and anaemia associated with T-cell large granular lymphocyte leukaemia responds to fludarabine with minimal toxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9092691" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Treatment of refractory large granular lymphocytic leukemia with 2-chlorodeoxyadenosine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15009063" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Fludarabine, mitoxantrone and dexamethasone in the treatment of indolent B- and T-cell lymphoid malignancies in Chinese patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12804646" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : 2-deoxycoformycin in the treatment of T-large granular lymphocyte leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17525720" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Fludarabine, mitoxantrone and dexamethasone as first-line treatment for T-cell large granular lymphocyte leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18292613" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : T-cell large granular lymphocytic leukaemia: successful response to 2-deoxycoformycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19306076" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : T-cell large granular lymphocytic (T-LGL) leukemia: a single institution experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29228628" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29674644" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34133042" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Ruxolitinib for refractory large granular lymphocyte leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18550263" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Outcomes of splenectomy in T-cell large granular lymphocyte leukemia with splenomegaly and cytopenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9633895" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Large granular lymphocyte leukaemia occurring after renal transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3479187" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Evaluation of splenectomy in large granular lymphocyte leukaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1712868" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : [Chronic lymphocytic leukemia with peripheral T lymphocytes expressing CD 2+, CD 3+, CD 4-, CD 8-, CD 16+, and CD 56+ and lymph-node lymphocytes expressing CD 2+, CD 3-, CD 4-, CD 8-, CD 16+, CD 38+, and CD 56+].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9519776" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Induction of clinical remission in T-large granular lymphocyte leukemia with cyclosporin A, monitored by use of immunophenotyping with Vbeta antibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17205534" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Aggressive T-cell large granular lymphocyte leukemia: a case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7833488" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Allogeneic bone marrow transplantation for CD3+/TCR gamma delta+ large granular lymphocyte proliferation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9504633" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Multidrug resistance analysis in lymphoproliferative disease of large granular lymphocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1363104" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Preferential expression and activity of multidrug resistance gene 1 product (P-glycoprotein), a functionally active efflux pump, in human CD8+ T cells: a role in cytotoxic effector function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1360267" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7680244" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Expression of multidrug resistance P-glycoprotein on peripheral blood mononuclear cells of patients with granular lymphocyte-proliferative disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23869084" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Long-term remission of T-cell large granular lymphocyte leukemia associated with rheumatoid arthritis after rituximab therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28804660" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Large Granular Lymphocytic Leukemia: A Report of Response to Rituximab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26922203" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Rheumatoid arthritis and associated large granular lymphocytic leukemia--successful treatment with rituximab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2403836" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Clinical course and prognosis of the lymphoproliferative disease of granular lymphocytes. A multicenter study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23212516" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Phase 1 trial of IL-15 trans presentation blockade using humanized Mikβ1 mAb in patients with T-cell large granular lymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26449659" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Tofacitinib as a novel salvage therapy for refractory T-cell large granular lymphocytic leukemia.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
